| 000 | 01521 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250513130629.0 | ||
| 264 | 0 | _c19971202 | |
| 008 | 199712s 0 0 eng d | ||
| 022 | _a0114-5916 | ||
| 024 | 7 |
_a10.2165/00002018-199717040-00004 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSunder-Plassmann, G | |
| 245 | 0 | 0 |
_aSafety aspects of parenteral iron in patients with end-stage renal disease. _h[electronic resource] |
| 260 |
_bDrug safety _cOct 1997 |
||
| 300 |
_a241-50 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnemia, Iron-Deficiency _xdrug therapy |
| 650 | 0 | 4 |
_aCitric Acid _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Combinations |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 |
_aErythropoietin _xtherapeutic use |
| 650 | 0 | 4 |
_aFerric Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aFerric Oxide, Saccharated |
| 650 | 0 | 4 |
_aFerrous Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aGlucaric Acid |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 |
_aIron Compounds _xadministration & dosage |
| 650 | 0 | 4 |
_aIron Overload _xcomplications |
| 650 | 0 | 4 |
_aIron-Dextran Complex _xadministration & dosage |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xcomplications |
| 650 | 0 | 4 |
_aSorbitol _xadministration & dosage |
| 700 | 1 | _aHörl, W H | |
| 773 | 0 |
_tDrug safety _gvol. 17 _gno. 4 _gp. 241-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00002018-199717040-00004 _zAvailable from publisher's website |
| 999 |
_c9323276 _d9323276 |
||